BioXcel Therapeutics, Inc.
BTAI
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new tā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.83
Price+2.81%
$0.05
1Y
Price
Market Cap
$35.954m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-13210.0%
EBITDA Margin-15989.2%
Net Profit Margin-10479.2%
Free Cash Flow MarginRevenue
$868k
-61.7%
1y CAGR+90.2%
3y CAGR+67.6%
5y CAGREarnings
-$50.950m
+14.5%
1y CAGR+24.4%
3y CAGR+4.4%
5y CAGREPS
-$12.67
+46.1%
1y CAGR+39.4%
3y CAGR+18.1%
5y CAGRBook Value
-$107.667m
$25.789m
Assets$133.456m
Liabilities$108.685m
DebtDebt to Assets
421.4%
-2.8x
Debt to EBITDAFree Cash Flow
-$55.765m
+22.6%
1y CAGR+20.6%
3y CAGR-0.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company